AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
09 11월 2023 - 10:05PM
AIM ImmunoTech Inc. (NYSE American:
AIM) (“AIM” or the “Company”), announced today that
management will host a conference call and webcast to discuss the
Company’s Q3 2023 operational and financial results on Wednesday,
November 15, 2023 at 8:30 AM ET.
The call will be hosted by members of AIM’s
leadership team, Thomas K. Equels, Chief Executive Officer and
Christopher McAleer, PhD, Scientific Officer. Interested
participants and investors may access the conference call by
dialing (877) 407-9219 (domestic) or (201) 689-8852 (international)
and referencing the AIM ImmunoTech Conference Call. The webcast
will be accessible on the Events page of the Investors section of
the Company’s website, aimimmuno.com, and will be archived for 90
days following the live event.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders and viral diseases,
including COVID-19. The Company’s lead product is a first-in-class
investigational drug called Ampligen® (rintatolimod), a dsRNA and
highly selective TLR3 agonist immuno-modulator with broad spectrum
activity in clinical trials for globally important cancers, viral
diseases and disorders of the immune system.
For more information, please
visit aimimmuno.com and connect with the Company
on Twitter, LinkedIn, and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
AIM ImmunoTech (AMEX:AIM)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024